Lanraplenib (GS-9876) structure
|
Common Name | Lanraplenib (GS-9876) | ||
---|---|---|---|---|
CAS Number | 1800046-95-0 | Molecular Weight | 443.50 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C23H25N9O | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Lanraplenib (GS-9876)Lanraplenib (GS-9876) is a highly selective and oral SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans[1][2][3]. |
Name | Lanraplenib |
---|
Description | Lanraplenib (GS-9876) is a highly selective and oral SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans[1][2][3]. |
---|---|
Related Catalog | |
Target |
IC50: 9.5 nM (SYK)[1] |
In Vitro | GS-9876 inhibits anti-IgM stimulated phosphorylation of AKT, BLNK, BTK, ERK, MEK, and PKCδ in human B cells with EC50 values of 24-51 nM. GS-9876 inhibits anti-IgM mediated CD69 and CD86 expression on B-cells (EC50=112±10 nM and 164±15 nM, respectively) and anti-IgM /anti-CD40 co-stimulated B cell proliferation (EC50=108±55 nM). In human macrophages, GS-9876 inhibits IC-stimulated TNFα and IL-1β release (EC50=121±77 nM and 9±17 nM, respectively)[1]. GS-9876 inhibits glycoprotein VI (GPVI)-induced phosphorylation of linker for activation of T cells and phospholipase Cγ2, platelet activation and aggregation in human whole blood, and platelet binding to collagen under arterial flow[2]. |
References |
Molecular Formula | C23H25N9O |
---|---|
Molecular Weight | 443.50 |